NCT07200908View on ClinicalTrials.gov

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

PHASE3RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

September 30, 2029

Conditions
Chronic Hepatitis D Infection
Interventions
DRUG

Brelovitug 300 mg

Route of administration- Subcutaneous Injection

DRUG

Bulevirtide 2 mg and Brelovitug - 300 mg

Route of Administration- Subcutaneous Injection

Trial Locations (4)

8036

RECRUITING

Medical University of Graz, Graz

HU16 5JQ

RECRUITING

Hull University Teaching Hospitals, Cottingham

E12ES

RECRUITING

Barts Health NHS Trust, London

SE5 9RS

RECRUITING

King's College Hospital NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

Bluejay Therapeutics, Inc.

INDUSTRY